

Cornelis J M Melief

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7535581/publications.pdf>

Version: 2024-02-01

27
papers

2,624
citations

279798

23
h-index

526287

27
g-index

28
all docs

28
docs citations

28
times ranked

3282
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 583-597. | 3.4 | 9 |
| 2 | Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. <i>Oncolmunology</i> , 2018, 7, e1490855. | 4.6 | 10 |
| 3 | TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients. <i>Oncotarget</i> , 2016, 7, 67087-67100. | 1.8 | 43 |
| 4 | Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. <i>Journal of General Virology</i> , 2015, 96, 1478-1483. | 2.9 | 10 |
| 5 | A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. <i>Oncotarget</i> , 2015, 6, 32228-32243. | 1.8 | 58 |
| 6 | Addition of interferon α to the p53 α SLP α vaccine results in increased production of interferon α in vaccinated colorectal cancer patients: A phase I/II clinical trial. <i>International Journal of Cancer</i> , 2013, 132, 1581-1591. | 5.1 | 50 |
| 7 | Local immunomodulation for cancer therapy: Providing treatment where needed. <i>Oncolmunology</i> , 2013, 2, e26493. | 4.6 | 24 |
| 8 | Colorectal cancer vaccines in clinical trials. <i>Expert Review of Vaccines</i> , 2011, 10, 899-921. | 4.4 | 23 |
| 9 | The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. <i>International Journal of Cancer</i> , 2011, 128, 379-389. | 5.1 | 44 |
| 10 | Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. <i>Journal of Pathology</i> , 2009, 218, 222-231. | 4.5 | 87 |
| 11 | Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. <i>International Journal of Cancer</i> , 2008, 122, 486-494. | 5.1 | 74 |
| 12 | Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. <i>International Journal of Cancer</i> , 2008, 123, 146-152. | 5.1 | 36 |
| 13 | Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer. <i>International Journal of Cancer</i> , 2008, 123, 838-845. | 5.1 | 29 |
| 14 | Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. <i>Nature Reviews Cancer</i> , 2008, 8, 351-360. | 28.4 | 508 |
| 15 | Design and development of synthetic peptide vaccines: past, present and future. <i>Expert Review of Vaccines</i> , 2007, 6, 591-603. | 4.4 | 130 |
| 16 | Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. <i>International Journal of Cancer</i> , 2006, 118, 675-683. | 5.1 | 41 |
| 17 | Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. <i>International Journal of Cancer</i> , 2006, 118, 950-956. | 5.1 | 59 |
| 18 | Competition-Based Cellular Peptide Binding Assay for HLA Class I. <i>Current Protocols in Immunology</i> , 2004, 61, Unit 18.12. | 3.6 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. <i>International Journal of Cancer</i> , 2003, 107, 425-433. | 5.1 | 28 |
| 20 | Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/Kb-transgenic mice. <i>International Journal of Cancer</i> , 2001, 91, 385-392. | 5.1 | 85 |
| 21 | Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes. <i>International Journal of Cancer</i> , 2001, 91, 612-618. | 5.1 | 129 |
| 22 | Expression of three extracellular matrix degradative enzymes in bladder cancer. <i>International Journal of Cancer</i> , 2001, 95, 295-301. | 5.1 | 106 |
| 23 | Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. <i>International Journal of Cancer</i> , 2000, 87, 253-260. | 5.1 | 44 |
| 24 | Immature Dendritic Cells Acquire Cd8+Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cell-Independent or-Dependent Stimuli. <i>Journal of Experimental Medicine</i> , 2000, 192, 145-150. | 8.5 | 173 |
| 25 | Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein. <i>Journal of Experimental Medicine</i> , 1999, 190, 1033-1038. | 8.5 | 305 |
| 26 | CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. <i>Nature Medicine</i> , 1999, 5, 774-779. | 30.7 | 439 |
| 27 | CD80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic T-Cell Responses Directed at Patient Specific Minor Histocompatibility Antigens and Leukemia-Associated Antigens. <i>Blood</i> , 1998, 92, 1677-1684. | 1.4 | 57 |